The identification of a drug that stimulates endogenous myelination and spares axon degeneration during multiple sclerosis (MS) could potentially reduce the rate of disease progression. Using experimental autoimmune encephalomyelitis (EAE), a mouse model of MS, we have previously shown that prophylactic administration of the estrogen receptor (ER) β ligand 2,3-bis(4-hydroxyphenyl)-propionitrile (DPN) decreases clinical disease, is neuroprotective, stimulates endogenous myelination, and improves axon conduction without altering peripheral cytokine production or reducing central nervous system (CNS) inflammation. Here, we assessed the effects of therapeutic DPN treatment during peak EAE disease, which represents a more clinically relevant treatment paradigm. In addition, we investigated the mechanism of action of DPN treatment-induced recovery during EAE. Given that prophylactic and therapeutic treatments with DPN during EAE improved remyelination-induced axon conduction, and that ER (α and β) and membrane (m)ERs are present on oligodendrocyte lineage cells, a direct effect of treatment on oligodendrocytes is likely. DPN treatment of EAE animals resulted in phosphorylated ERβ and activated the phosphatidylinositol 3-kinase (PI3K)/serine-threonine-specific protein kinase (Akt)/mammalian target of rapamycin (mTOR) signaling pathway, a pathway required for oligodendrocyte survival and axon myelination. These results, along with our previous studies of prophylactic DPN treatment, make DPN and similar ERβ ligands immediate and favorable therapeutic candidates for demyelinating disease.
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Introduction
The development of directly neuroprotective treatments that prevent the loss of oligodendrocytes (OLs) and promote the proliferation and differentiation of progenitors (OLPs) is a treatment goal for multiple sclerosis (MS). Using experimental autoimmune encephalomyelitis (EAE), a mouse model of MS, a significant reduction in clinical symptoms has been shown with estradiol, estriol, and other estrogen receptor (ER) ligand treatments (Crawford et al., 2009a (Crawford et al., , 2010 Matejuk et al., 2004; Strigard et al., 1990; Tiwari-Woodruff et al., 2007) . The success of estrogens in ameliorating EAE clinical disease within the laboratory setting prompted clinical trials in Europe and the United States using estrogen therapy in human MS patients. However, synthetic estrogen supplementation is associated with increased risk of breast and uterine cancer, heart disease, and stroke (Prentice et al., 2009 ). Most of these side effects are thought to be mediated through ERα, not ERβ (Caringella et al., 2011) . As a result, interest in ERβ as a target for neuroprotective therapy has become desirable.
To this end, we have shown that prophylactic administration of the ERβ ligand 2,3-bis(4-hydroxyphenyl)-propionitrile (DPN) decreases clinical features of EAE, is neuroprotective, stimulates endogenous
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Abbreviations: MS, multiple sclerosis; EAE, experimental autoimmune encephalomyelitis; CNS, central nervous system; ER, estrogen receptor; DPN, 2,3-bis(4-hydroxyphenyl)-propionitrile; OL, oligodendrocyte; OLP, oligodendrocyte progenitor; RRMS, relapsingremitting MS; PLP_EGFP, proteolipid protein-enhanced green fluorescent protein; MOG, myelin oligodendrocyte glycoprotein; CC, corpus callosum; CAP, compound action potential; IPI, interpulse interval; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling; CD, cluster of differentiation; GAPDH, glyceraldehyde phosphate dehydrogenase; PI3K, phosphatidylinositol 3-kinase; Akt, serine-threonine-specific protein kinase; mTOR, mammalian target of rapamycin; P70S6K, P70 ribosomal protein S6 kinase; PTEN, phosphatase and tensin homolog; GFAP, glial fibrillary acidic protein; MBP, myelin basic protein; PDGFRα, platelet-derived growth factor receptor-α; olig2, OL transcription factor 2; CC1, adenomatous polyposis coli; DAPI, 4′,6-diamidino-2-phenylindole; BDNF, brainderived neurotrophic factor; IGF-1, insulin-like growth factor-1; Trk-B, tyrosine kinase receptor-type 2; IGFR-1, insulin-like growth factor receptor 1.
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